The changing epidemiology of kidney cancer

R. Rendon

Abstract:Kidney cancer accounts for about 3% of all adult cancers.1 The incidence of renal cell carcinoma (RCC) in Canada and the United States is increasing at a rate of 2% to 2.5% per year.1,2 The incidence of RCC in the United States increased from 7.1 per 100 000 in the early 1980s to 10.9 in 2002. Most of this rise is at the expense of incidentally detected small renal masses (SRMs) likely due to the more frequent use of abdominal imaging. In 1970, 10% of RCCs were detected incidentally, compared with more than 60% in 1998. These incidentally detected SRMs portend a better prognosis than symptomatic ones. Patard and colleagues described that the 73 months disease-free survival for incidentally detected tumours was 93% compared with 59% for those that presented with symptoms. These incidentally detected SRMs are more likely to be of benign histology, smaller, of lower stage and lower grade.3 Cooperberg and colleagues demonstrated that the mean tumour size at diagnosis decreased from 4.1 to 3.6 cm between 1993 and 2004.4 The resected tumour size from surgical series dropped from an average largest diameter of 7.8 to 5.3 cm between 1989 and 1998.5 There has also been an increase in the proportion of renal masses £3 cm and £2 cm between 1993 and 2004 (32.5 vs. 43.4% and 24.1 vs. 29.4%, respectively). In addition, it has been described that 85% of tumours £4 cm in size were localized to the kidney (stage T1a) as opposed to 32% of those between 4 and 7 cm. Pearson and colleagues reported that only 7.2% of tumours £4 cm are stage pT3a.6 From a sample size of 18 818 patients, Rothman and colleagues reported that 86% of patient with tumours smaller than 4cm in diameter have a low Fuhrman grade.7 Patients in the seventh to ninth decades of life have experienced the largest increase in incidence with a tenfold rise between 1935-39 and 1985-89.2 This particular age group has the largest amount of comorbidities. It has been demonstrated that the 5-year overall mortality for no cancer causes and other cancers is much higher than that of kidney cancer in patients older than 65 years of age.8 While disease characteristics have changed over the last 30 years, aggressive treatment remains the standard of care for incidentally detected SRMs. Between 1983 and 2002, the incidence of renal surgery in the United States increased from 0.9 to 3.6 per 100 000, mostly at the expense of SRMs. This increase in surgical treatment does not appear to translate into better outcomes. The mortality rate for all renal tumours in the United States has increased.2,9 Furthermore, Russo and colleagues demonstrated that progression-free survival and overall survival rates have not changed between 1989 and 2004 after resection of localized kidney cancer.10 These changing trends demonstrate a treatment disconnect between the stage migration of RCC and increased surgical management and the rising disease specific mortality rate of RCC. This observation questions the risk that these incidentally detected SRMs truly represents.

Medicine